Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure

American Journal of Kidney Diseases

Volumn 29, Issue 1, 1997, Pages 66-71

  Chertow, Glenn M ^a   Burke, Steven K ^b   Lazarus, J Michael ^b   Stenzel, Kurt H ^b   Wombolt, Duane ^b   Goldberg, Dennis ^b   Bonventre, Joseph V ^b   Slatopolsky, Eduardo ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

cholesterol; chronic renal failure; hyperparathyroidism; Hyperphosphatemia; randomized controlled trial

Indexed keywords

ALLYLAMINE DERIVATIVE; PHOSPHATE BINDING AGENT;

ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERPHOSPHATEMIA; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; RANDOMIZED CONTROLLED TRIAL;

EID: 0031036316     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90009-3     Document Type: Article

References (27)

1. Kaehny WD, Hegg AP, Alfrey AC: Gastrointestinal absorption of aluminum from aluminum-containing antacids. N Engl J Med 296:1389-1390, 1977
2. Goodman WG: Bone disease and aluminum: Pathogenic considerations. Am J Kidney Dis 6:330-335, 1985
3. Drucke TB, Lacour B, Touam M, Jacquel JP, Plachot JJ, Cournot-Witmer G, Galle P: Effect of aluminum on hematopoiesis. Kidney Int Suppl 18:S45-S48, 1986
4. Arieff AI: Aluminum and the pathogenesis of dialysis encephalopathy. Am J Kidney Dis 6:317-321, 1985
5. Slatopolsky EA, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161, 1986
6. Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus D, Delmez J: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 36:897-903, 1989
7. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690-695, 1989
8. Ginsburg D, Kaplan E, Katz A: Hypercalcemia after oral calcium carbonate therapy in dialysis patients on chronic hemodialysis. Lancet 1:1271-1275, 1973
9. Gonella M, Calabrese G, Vagelli G, Pratesi G, Lamon S, Talrico S: Effects of high CaCO3 supplements on serum calcium and phosphorus in patients on regular hemodialysis treatment. Clin Nephrol 24:147-150, 1985
10. Meric F, Yap P, Bia MJ: Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 16:459-464, 1990
11. Burke SK, Goldberg DJ, Bonventre JV, Slatopolsky E: RenaGel, a calcium and aluminum free phosphate binder inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 11:A40, 1996 (abstr)
12. Burke BS: The dietary history as a tool in research. J Am Diet Assoc 23:1041-1046, 1947
13. Posner BM, Borman CL, Morgan JL, Borden WS, Ohls JC: The validity of a telephone-administered, 24-hour dietary recall methodology. Am J Clin Nutr 36:546-553, 1982
14. Kleinbaum DG, Kupper LL, Muller KE: Straight-line regression analysis, in Applied Regression Analysis and other Multivariable Measures. Boston, MA, Duxbury Press, 1988, pp 41-79
15. Pabst G, Jaeger H: Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 38:5-10, 1990
16. Slatopolsky E, Caglar S, Pennell JP, Taggart J, Canterbury M, Reiss E, Bricker NS: On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 50:492-499, 1971
17. Slatopolsky E, Bricker NS: The role of phosphate restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 4:141-145, 1973
18. Portale AA, Booth BE, Halloran BP, Morris RC Jr: Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxy-vitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580-1589, 1984
19. Lopez-Hilker S, Dusso A, Rapp NS, Martin KJ, Slatopolsky E: Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 259:F432-F437, 1990
20. Lucas PA, Brown RC, Woodhead JS, Coles GA: 1,25-Dihydroxycholecalciferol and parathyroid hormone in advanced chronic renal failure: Effects of simultaneous protein and phosphorus restriction. Clin Nephrol 25:7-10, 1986
21. Schaefer K, Erley CM, von Herrath D, Stein G: Calcium salts of ketoacids as a new treatment strategy for uremic hyperphosphatemia. Kidney Int 36:S136-S139, 1989
22. Aparicio M, Combe C, Lafage MH, de Precigout V, Potaux L, Bouchet JL: In advanced renal failure, dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the level of calcitriol. Nephron 63:122-123, 1993
23. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ: Phosphorus restriction prevents parathyroid gland growth: High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534-2540, 1996
24. Hou SH, Zhao J, Ellman CF, Hu J, Griffin Z, Spiegel DM, Bourdeau JE: Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 18:217-224, 1991
25. Delmez JA, Slatopolsky E, Martin KJ, Gearing B, Harter H: Minerals, vitamin D and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int 21:862-867, 1982
26. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990
27. Toto RD, Vega GL, Grundy SM: Mechanisms and treatment of dyslipidemia of renal disease. Curr Opin Nephrol Hypertens 2:784-790, 1993